NEW YORK –February 11, 2010–Southridge LLC (“Southridge”), an investment firm providing capital to publicly listed companies, is pleased to announce that its affiliated fund has closed a private equity agreement for up to $7.5 million in equity financing with PuraMed BioScience.

Stephen Hicks, founder of Southridge Capital, said, “Southridge is very pleased to provide equity capital financing for this innovative market leader in the over-the-counter consumer market for alternative health remedies”.

PuraMed BioScience was created to secure two unique opportunities. The first is to build a corporeal business, quickly, starting with its three core products: LipiGesic™ H (for acute relief of tension headaches) , LipiGesic™ M (for acute relief of migraine headaches) and PuraMed™ PM (for insomnia). All are safe, effective and target a very large over-the-counter (OTC) consumer market, together worth more than $2 billion in the U.S. Each individual product is unique to its class. The second opportunity is to become a household name in the alternative health remedy and highly fragmented OTC natural market by announcing an alternative remedy line for common ailments.

Southridge Capital explores investments in emerging growth markets, domestically and in internationally. Southridge Capital has now successfully participated in providing over $1.7 billion in capital funding to companies in the United States, the United Kingdom, China and Australia as well as others.

About Southridge Capital
Also known as Southridge LLC is a diversified financial holding company offering a wide range of products and services, including Investment Banking, Fund Management, Wealth Management and Business Solutions and Merchant Banking. For more information please visit www.southridgellc.com. at Southridge Capital or Southridge CapitalBlog